Q-omics provides the consensus-scored RNF183 profile across patient tissues and cancer cell-line models. RNF183 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNF183 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, RNF183 RNA expression shows 15,394 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where RNF183 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF183 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF183 survival associations across molecular data types. RNF183 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF183 RNA expression–survival associations across cancer types. High RNF183 expression shows unfavorable associations in LIHC, but favorable associations in KIRC, UCEC, KIRP, BRCA and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNF183 RNA expression.
This table summarizes RNF183 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RNF183. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF183 shows lower tumor expression in HNSC and KICH and higher tumor expression in COAD, THCA, LUAD and UCEC. The COAD box plot shows higher RNF183 RNA expression in tumor versus normal tissue (log2 FC = +2.084, t-test p < 0.001).
This table shows molecular features associated with RNF183 in patient tissues and cancer cell lines. In patient samples, RNF183 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF183 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_SCLC.
